On May 18, 2018, the U.S. Food and Drug Administration (FDA) issued a warning letter to Front Range Kratom regarding the sale and distribution of kratom products. This letter highlighted serious concerns about the safety, efficacy, and labeling practices associated with the company’s offerings. The FDA identified multiple violations, including unsubstantiated health claims and misleading marketing tactics that suggested kratom as a safe and effective treatment for various medical conditions. Additionally, the agency emphasized the potential health risks associated with kratom use, such as addiction and adverse effects. This warning underscores the ongoing regulatory scrutiny surrounding kratom, reflecting broader public health concerns and the need for further research into its safety profile. The letter serves as a critical reminder for companies involved in the herbal supplement industry to adhere to federal regulations and prioritize consumer safety.
Menu
